I would note it specifies “cancer types” and not merely “sub types”, if correct we will get to understand the breadth of Zantrene’s super powers.
This will help convey value to Pharma and the market. I understand as a general rule of thumb most drugs work on single indication / targets. So if we improve on this things will be looking good!
Ann: December 2022 Preclinical & Clinical Programs Update, page-11
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.79 |
Change
-0.075(4.02%) |
Mkt cap ! $304.8M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.86 | $1.76 | $348.2K | 192.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5612 | $1.77 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.79 | 3567 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.78 |
Change
-0.075 ( 5.38 %) |
||||
| Open | High | Low | Volume | ||
| $1.81 | $1.86 | $1.76 | 27553 | ||
| Last updated 15.55pm 14/06/2024 ? | |||||
| RAC (ASX) Chart |